Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly

  title={Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly},
  author={E. Perucca and J. Parini and A. Albrici and M. Visconti and E. Ferrero},
  journal={European Journal of Drug Metabolism and Pharmacokinetics},
SummaryThe kinetics of the nootropic drug oxiracetam was studied in 6 elderly female patients (age range 69–96 years) in good physical condition. After a single oral dose (800 mg), serum oxiracetam levels reached a peak (25 ± 6 ug/ml) within 1–3 h and declined thereafter with a half-life of 3 to 6 h. Eighty-four percent of the administered dose was recovered in urine as unchanged drug within 24 h. During a maintenance regimen (800 b.i.d. at 8 a.m. and 2 p.m.) for 7 days oxiracetam did not show… Expand
Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose
The dosage of oxiracetam in renal insufficient patients was evaluated in order to reach a mean steady-state concentration level in plasma close to that in patients with normal renal function, and the adjusted daily dose would be 25% of the dose given to a patient withnormal renal function. Expand
Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with non-geriatric healthy subjects
No modification of the pharmacokinetics of oxiracetam was recorded after repeated administration in elderly patients as shown by the good agreement between the oxir acetam steady-state level in plasma predicted from the concentrations after the first dose and the concentrations actually measured after repeated dosing. Expand
Pharmacokinetic comparisons of S-oxiracetam and R-oxiracetam in beagle dogs
The study showed that oxiracetam enantiomers maintained their original conformation when administered orally to beagle dogs, which showed that the different effects between S-ORT and R-ORT may be partly associated with their distinctive absorption at least. Expand
Pharmacokinetics of enantiomers of oxiracetam in rats
Purpose: To investigate the differences in pharmacokinetics of S-oxiracetam (S-ORT) and Roxiracetam (R-ORT) in rats. Methods: Sprague-Dawley rats (20) were randomly divided into two groups (ten ratsExpand
A Study of Fasoracetam's Solid State Forms: A Potential Anti-Alzheimer Pharmaceutical.
Under ambient conditions, the hydrate form I is found to be the most stable form, showing a melting point of 57C, which could cause problems when formulating the hydrated form and impact the storage conditions of the compound. Expand


Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers
The kinetics of oxiracetam after single intravenous and oral doses (2000 mg) were investigated in four healthy volunteers and the decline in serum levels showed a prolonged, rapid phase followed by a delayed terminal phase. Expand
Biochemical Studies on the Nootropic Drug, Oxiracetam, in Brain
It is assumed that oxiracetam acts on the turnover of the phospholipids more than on their rate of synthesis from injected precursors, when added to the incubation medium or administered subacutely to animals. Expand
Experimental Behavioral Studies with Oxiracetam on Different Types of Chronic Cerebral Impairment
Summary: Oxiracetam (4-hydroxy-2-oxo-1-pyrrolidine acetamide) is a novel compound effective in improving learning and memory in normal animals as well as in animals with acute cerebral impairmentExpand
The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double‐blind controlled study with piracetam)
Itil, T.M., G.N. Menon, M. Bozak, and A. Songar: The effects of oxiracetam, (ISF 2522) in patients with organic brain syndrome (a double‐blind controlled study with piracetam). Drug Dev. Res.Expand
Drug disposition in old age.
THE appropriate and rational use of drugs by the elderly is a matter of growing medical and social concern. Life expectancy in the Western world currently stands at 69 years for men and 77 years fo...
CNS effects of ISF 2522, a new nootropic. A phase I safety and CNS efficacy study with quantitative pharmacoEEG and pharmaco-psychology
  • Curr. Ther. Res
  • 1975